Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.

Purpose: Zanubrutinib (BGB-3111) is a potent Bruton's tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochrome P450 3A (CYP3A) in vitro. We evaluated the effect of steady-state rifampin (a strong CYP3A induc...

Descripción completa

Detalles Bibliográficos

Publicado en:	Cancer Chemotherapy & Pharmacology Vol. 85; no. 2; pp. 391 - 400
Autores principales:	Mu, Song, Tang, Zhiyu, Novotny, William, Tawashi, Manal, Li, Ta-Kai, Ou, Ying, Sahasranaman, Srikumar
Formato:	research Journal Article
Publicado:	Springer Nature Feb2020
Acceso en línea:	Ver este registro en EBSCOhost